Evaluation of the clinical remission and its sustainment after discontinuation of infliximab in patients with rheumatoid arthritis who receive "programmed" treatment in randomized controlled trial
Phase 4
- Conditions
- Rheumatoid Arthritis
- Registration Number
- JPRN-UMIN000005113
- Lead Sponsor
- niversity of Occupational and Environmental Health, Japan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 450
Inclusion Criteria
Not provided
Exclusion Criteria
1) patients who use steroid over 10mg/day (prednisolone-equivalent), 2) SDAI =< 11.0, 3) severe infection, 4) active tuberculosis, 5) demyelinating disease, 6) congestive heart failure, 7) Patient who is lactating, pregnant, possibly pregnant or do not agree with anti-conception during the trial and 6 month after the last administration of IFX, 8) patients who are inadequate to enter this trial due to the other reasons by physician's judgments
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method